A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Abstract

A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study, and the neurological status of ‘Withdrawn’ patients was assessed at a 10-year long-term follow-up (LTFU) visit. Modified intention-to-treat (mITT, n=232) patients received ≥ 1 GA dose since 1991; ‘Ongoing’ patients (n=108) continued in November 2003. Of 124 patients, 50 Withdrawn patients returned for LTFU. Patients were evaluated every six months (EDSS). Mean GA exposure was 6.99, 10.1 and 4.26 years for mITT, Ongoing, and Withdrawn/LTFU patients, respectively. While on GA, mITT relapse rates declined from 1.18/year prestudy to ∼1 relapse/5 years; median time to ≥ 1 EDSS point increase was 8.8 years; mean EDSS change was 0.739±1.66 points; 58% had stable/improved EDSS scores; and 24, 11 and 3% reached EDSS 4, 6 and 8, respectively. For Ongoing patients, EDSS increased 0.509±1.65; 62% were stable/improved; and 24, 8 and 1% reached EDSS 4, 6 and 8, respectively. For Withdrawn patients at 10-year LTFU, EDSS increased 2.249±1.86; 28% were stable/improved; and 68, 50 and 10% reached EDSS 4, 6 and 8, respectively. While on GA nearly all patients (mean disease duration 15 years) remained ambulatory. At LTFU, Withdrawn patients had greater disability than Ongoing patients.

Keywords

disability disease modifying therapy EDSS glatiramer acetate immunomodulator relapse relapsing-remitting multiple sclerosis

Get full access to this article

View all access options for this article.

References

Oger J , Freedman M. Consensus statement of the Canadian MS Clinics Network on the use of disease modifying agents in multiple sclerosis . Can J Neurol Sci 1999; 26: 274-275 .

Weinshenker BG. The natural history of multiple sclerosis . Neurol Clin 1995; 13: 119-146 .

Miller A , Cohen J , Ford C , Garmany G , Goodman A , Green B et al. National Multiple Sclerosis Society (NMSS): disease management consensus statement. National MS Society , 2005.

The PRISMS (Prevention of Relapses and Disability by Interferon-B-1a Subcutaneously in Multiple Sclerosis) Study Group , and the University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-b1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 1996; 39: 285-294 .

FDA Public Health Advisory. Suspended marketing of Tysabri (natalizumab). Retrieved 31 March 2005, from http://www.fda.gov/cder/drug/advisory/natalizumab.htm

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology 1995; 45: 1268-1276 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability . Neurology 1998; 50: 701-708 .

10.

Johnson KP , Brooks BR , Ford CC , Goodman A , Lisak RP , Meyers LW et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial . Mult Scler 2003; 9: 585-591 .

11.

Johnson KP , Brooks BR , Ford CC , Goodman A , Guarnaccia J , Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years . Mult Scler 2000; 6: 255-266 .

12.

Johnson KP , Ford CC , Lisak RP , Wolinsky JS. Glatiramer acetate (Copaxone®): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data . Acta Neurol Scand 2005; 111: 42-47 .

13.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

14.

Clanet M , Kappos L , Hartung H-P , Hohlfeld R. The European IFNβ-1a dose-comparison study . Mult Scler 2004; 10: 139-144 .

15.

Kappos L , Stam Moraga M , Alsop J , The PRISMS Study Group . Long-term tolerability of interferon Beta- 1a in relapsing-remitting multiple sclerosis: 6-year safety follow-up of the PRISMS study . Presented at the Joint Meeting of the American/European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), Baltimore, MD, USA, 18-22 September, 2002: 334-334 .

16.

Yong VW. Differential mechanisms of action of inter-feron-b and glatiramer acetate in MS . Neurology 2002; 59: 802-808 .

17.

Gran B , Tranquill LR , Chen M , Bielekova B , Zhou W , Dhib-Jalbut S et al. Mechanisms of immunomodulation by glatiramer acetate . Neurology 2000; 55: 1704-1714 .

18.

Ragheb S , Abramczyk S , Lisak D , Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T cells . Mult Scler 2001; 7: 43-47 .

19.

Neuhaus O , Farina C , Wekerle H , Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis . Neurology 2001; 56: 702-708 .

20.

Chen M , Conway K , Johnson KP , Martin R , Dhib-Jalbut S. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years . J Neurologic Sci 2002; 201: 71-77 .

21.

Confavreux C , Vukusik S , Moreau T , Adeline P. Relapses and progression of disability in multiple sclerosis . N Engl J Med 2000; 343: 1430-1438 .

22.

Pittock SJ , Mayr WT , McClelland RL , Jorgensen NW , Weigand SD , Noseworthy JH et al. Change in MS-related disability in a population-based cohort . Neurology 2004; 62: 51-59 .

23.

Karlik S , Kirk S , Nicolle E , Kremenchutzky M , Rice GPA. Evidence for very long-term efficacy of interferon Beta 1B in relapsing remitting MS patients . Proceedings of the Seventeenth Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dublin, Ireland, 2001: 139-139 .

24.

Paty D , Kappos L , Stam Moraga M , Alsop J , Abdalla J. Long-term observational efficacy and safety follow-up of the PRISMS cohort . Proceedings of the Nineteenth Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (EC-TRIMS), Milan, Italy, 2003: 555-555 .

25.

Kinkel RP , Kollman C , Glassman A , Simon J , O’Connor P , Murray TJ et al. Interferon beta-1a (Avonex®) delays the onset of clinically definite MS over 5 years of treatment: results from the CHAMPIONS study . Presented at the Fifty-sixth Annual Meeting of the American Academy of Neurology, San Francisco, CA, USA, 2004: D29.006.

26.

Fisher E , Rudick RA , Simon JH , Cutter G , Baier M , Lee J-C et al. Eight-year follow-up study of brain atrophy in patients with MS . Neurology 2002; 59: 1412-1420 .